Mittie Doyle
CIK 1918845 · View on SEC EDGAR ↗
First SEC filing: June 18, 2026 · Latest: June 18, 2026
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 17, 2026 | AVTX | S 10b5-1 | 1,000 | $20.00 | $20,000 | 51,776 Direct | -1.89% | Disposed | 1.4% (price as of 2026-08-20) |
| Aug. 10, 2026 | AVTX | S 10b5-1 | 679 | $20.00 | $13,580 | 51,776 Direct | -1.29% | Disposed | 1.4% (price as of 2026-08-20) |
| July 27, 2026 | AVTX | S 10b5-1 | 1,000 | $20.00 | $20,000 | 51,776 Direct | -1.89% | Disposed | 1.4% (price as of 2026-08-20) |
| June 30, 2026 | AVTX | S 10b5-1 | 4,654 | $20.00 | $93,080 | 51,776 Direct | -8.25% | Disposed | 1.4% (price as of 2026-08-20) |
| June 23, 2026 | AVTX | S 10b5-1 | 1,450 | $18.00 | $26,100 | 51,776 Direct | -2.72% | Disposed | 12.6% (price as of 2026-08-20) |
| May 28, 2026 | AVTX | S | 679 | $16.00 | $10,864 | 47,122 | — | — | 26.7% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Aug. 17, 2026 | AVTX | Stock Option (Right to Buy) | Common Stock (1,000) | $12.65 | July 15, 2034 | 1,000 | Disposed |
| Aug. 10, 2026 | AVTX | Stock Option (Right to Buy) | Common Stock (679) | $8.04 | Jan. 28, 2035 | 679 | Disposed |
| July 27, 2026 | AVTX | Stock Option (Right to Buy) | Common Stock (1,000) | $12.65 | July 15, 2034 | 1,000 | Disposed |
| June 30, 2026 | AVTX | Stock Option (Right to Buy) | Common Stock (1,779) | $8.04 | Jan. 28, 2035 | 1,779 | Disposed |
| June 30, 2026 | AVTX | Stock Option (Right to Buy) | Common Stock (2,875) | $12.65 | July 15, 2034 | 2,875 | Disposed |
| June 23, 2026 | AVTX | Stock Option (Right to Buy) | Common Stock (1,450) | $8.04 | Jan. 28, 2035 | 1,450 | Disposed |
| June 16, 2026 | CGEM | Stock Option (Right to Buy) | Common Stock (21,781) | $13.55 | June 16, 2026 | 21,781 | Acquired |
| Aug. 7, 2025 | CGEM | Stock Option (Right to Buy) | Common Stock (79,456) | $7.03 | Aug. 7, 2035 | 79,456 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
AVTX
M.D., FACRChief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $512,500 | — | — | $1,030,429 | $229,600 | — | $8,028 | $1,780,557 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.